Clinical translation of polymeric microneedles for bioactive nanovesicle delivery in hypertrophic scar remodeling.
Ming Yu Chang, Bo Zhi Chen, Ling Liang et al.
✦ AI-curated · Sources linked
In 30 seconds
This prospective, single-center, open-label, single-arm study evaluated a 12-week protocol combining microplasma radiofrequency, poly(L-lactic acid) microneedles, and topical milk-derived bioactive nanovesicles in 26 patients with hypertrophic scars. At week 12, treatment was associated with reductions in Vancouver Scar Scale and POSAS Patient Scale scores, scar stiffness and thickness, and dermoscopic vascular and pigmentation densities. Microneedle channels closed rapidly; reactions were mild and transient, with no serious or systemic adverse events. The findings indicate short-term feasibility, tolerability, and preliminary clinical activity, but do not establish the contribution of individual components or comparative efficacy.
Key findings
- At week 12, the combined protocol was associated with reductions in VSS and POSAS Patient Scale scores, scar stiffness and thickness, and dermoscopic vascular and pigmentation densities.
- Microneedle-induced microchannels closed rapidly, and treatment-related reactions were mild and transient.
- No serious or systemic adverse events were observed.
Why it matters
Pathological scar tissue can impede delivery of macromolecules, making local treatment challenging. This study provides early clinical evidence that a protocol combining radiofrequency, polymeric microneedles, and bioactive nanovesicles can be delivered with short-term tolerability and measurable scar changes. The results are preliminary and do not show whether the nanovesicles or any other component independently produced the observed changes.
What to keep in mind
The study was single-center, open-label, and single-arm, with no comparator; it therefore cannot establish comparative efficacy or isolate the effects of individual treatment components. Follow-up was limited to 12 weeks.